iAtoday

We wish to inform you that Wegovy¹ will be covered as of November 15, 2024 in plans that include coverage of weight management drugs.

To promote optimal use of this drug while ensuring the long-term sustainability of group drug plans, reimbursement will be subject to prior authorization.

Weight management drug coverage

Preserving the physical and mental health of plan members through continued access to a comprehensive plan that meets their needs is an integral part of our PharmAssist drug management program.

That is why, for the health of these persons, we recommend that treatments for obesity and weight management be covered by drug plans, according to pre-established criteria.

As these treatments have an important preventive component, we believe that reducing excess weight can have significant, positive benefits for their health and, by the same token, for group insurance plan expenses.

Please do not hesitate to contact your iA Financial Group Account Executive if you have any questions, or if any of your groups would like to add weight management drug coverage to their group insurance plan.

Read the communiqué we will be sending to plan administrators on October 21.

 ¹ WEGOVY® (semaglutide injection) is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management.